期刊文献+

血浆置换联合化疗、免疫抑制剂治疗噬血细胞综合症合并血栓性血小板减少性紫癜的临床观察 被引量:7

Clinical observation of the combination of plasmapheresis with chemotherapy and immunosuppressants for treatment of patients with HPS and TTP
下载PDF
导出
摘要 目的观察血浆置换联合化疗、免疫抑制剂治疗罕见病——噬血细胞综合征合并血栓性血小板减少性紫癜的疗效。方法 2014年1-3月对本科两例噬血细胞综合征合并血栓性血小板减少性紫癜患者采用血浆置换联合环孢素、糖皮质激素、足叶乙甙方案进行治疗,随访至2015年3月。结果 2例患者血常规均恢复正常,发热、精神症状消失,肾功能恢复正常,骨髓嗜血现象消失,至今存活。结论血浆置换联合化疗、免疫抑制剂是治疗噬血细胞综合征合并血栓性血小板减少性紫癜的有效方法。 Objective To investigate the effect of the combination of plasmapheresis with chemotherapy and immunosuppressants for treatment of patients with hemophagocytic syndrome( HPS) and thrombotic thrombocytopenic purpura( TTP). Methods Two patients with HPS and TTP were salvaged by plasmapheresis combined with chemotherapy and immunosuppressants during January and March of 2014. Results After treatment,patients' temperature,blood cell count and renal function returned to normal; mental symptoms and hemophagocytic bone marrow phenomenon disappeared. Two patients have survived until now. Conclusion It is suggested that plasmapheresis combined with chemotherapy and immunosuppressants is an effective regimen for treatment of patient with HPS and TTP.
出处 《中国输血杂志》 CAS 北大核心 2015年第11期1316-1318,共3页 Chinese Journal of Blood Transfusion
关键词 血浆置换 化疗 免疫抑制剂 噬血细胞综合征 血栓性血小板减少性紫癜 plasmapheresis chemotherapy immunosuppressants HPS TTP
  • 相关文献

参考文献10

二级参考文献34

  • 1苏健,白霞,刘芳,高维强,余自强,王兆钺,阮长耿.血管性血友病因子裂解酶功能检测在血栓性血小板减少性紫癜诊断中的意义[J].中华检验医学杂志,2006,29(5):414-416. 被引量:1
  • 2Moake JL.Thrombotic microangiopathies[J].N Engl J Med,2002,347:589-600.
  • 3Sadler JE,Moake JL,Miyata T,et al.Recent advances in thrombotic thrombocytopenic purpura[J].Hematology (Am Soc Hematol Educ Program),2004,320:407-423.
  • 4Levine SP.Thrombotic thrombocytopenic purpura and other forms of nonimmunologic platelet destruction[A].In:Greer JP,Foerster J,Lukens JN,et al.Wintrobe's Clinical Hematology[M].Philadelphia:Lippoincott Williams & Wilkins,2004.1555-1564.
  • 5Henter JI, Home A, Arico M, et al. HLH- 2004: Diagnosis and therapeutic guidelines for hemophagocytic lymphohistiocytosis [ J ]. Pediatr Blood Cancer,2007,48(2) :124- 131.
  • 6SADLER J E. Von Willebrand factor,ADAMTS13,and thrombotic thrombocytopenic purpura[J]. Blood,2008,112:11-18.
  • 7SADLER J E, PONCZ M. Antibody-mediated throm-botic disorders : thrombotic thrombocytopenic purpuraand heparin-induced thrombocytopenia[M]//KAUS-HANSKY K,LICHTMAN M A’BEULTER E,et al.Williams Hematology. 8th ed. The McGraw-HillCompanies. Inc,2010:2163 - 2183.
  • 8KOKAME K,NOBE Y’KOKUBO Y,et al. FRETS-VWF73,a first fluorogenic substrate for ADAMTS13assay[J]. Br J Haematol, 2005,129 :93 -100.
  • 9BRESIN E,GASTOLDI S,DAINA E,et al. Ritux-imab as pre-emptive treatment in patients with throm-botic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies [J]. Thromb Haemost,2009,101:233-238.
  • 10Zur S U, Beutel K, Kolberg S, et al.Mutaion spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses ofPRF1, UNC13D, STX11 and RAB27A[J].Hum Murat, 2006, 27 ( 1 ) : 62-68.

共引文献109

同被引文献53

引证文献7

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部